TARANTINO, PAOLO
TARANTINO, PAOLO
Dipartimento di Oncologia ed Emato-Oncologia
Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclib
2025 C. Corti, A.R. Martin, P.T. Kurnia, J. Gómez Tejeda Zañudo, D.L. Abravanel, M.E. Hughes, T. Parker, P. Tarantino, G. Curigliano, T.A. King, E.A. Mittendorf, N.U. Lin, S.M. Tolaney
ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF BREAST CANCER.
2024 P. Tarantino
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience
2024 E. Crimini, G. Tini, P. Tarantino, L. Ascione, M. Repetto, P. Beria, A. Ranghiero, A. Marra, C. Belli, C. Criscitiello, A. Esposito, E. Guerini Rocco, M.C.P. Barberis, L. Mazzarella, G. Curigliano
Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment
2024 G. Corso, N. Fusco, E. Guerini-Rocco, M.C. Leonardi, C. Criscitiello, P. Zagami, E. Nicolo, G. Mazzarol, C. La Vecchia, F. Pesapane, C. Zanzottera, P. Tarantino, S. Petitto, B. Bianchi, G. Massari, A. Boato, A. Sibilio, A. Polizzi, G. Curigliano, A.M. De Scalzi, F. Lauria, B. Bonanni, M. Marabelli, A. Rotili, L. Nicosia, A. Albini, M. Calvello, R.A. Mukhtar, M.E. Robson, V. Sacchini, G. Rennert, V. Galimberti, P. Veronesi, F. Magnoni
A Comprehensive Review of the Growing Landscape of Endocrine and Biologic Treatments for Hormone Receptor-positive Breast Cancer
2024 D. Zhang, A. Ishag-Osman, C. Corti, P. Tarantino, L. Schlam
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
2023 G. Antonarelli, C. Corti, P. Tarantino, B.T. Salimbeni, P. Zagami, A. Marra, D. Trapani, S. Tolaney, J. Cortes, G. Curigliano
Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
2023 P. Tarantino, S.M. Tolaney, G. Curigliano
Response to letter entitled: Re: Evolution of low HER2 expression between early and advanced-stage breast cancer
2023 P. Tarantino, E. Nicolo, G. Curigliano
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
2023 L. Guidi, G. Pellizzari, P. Tarantino, C. Valenza, G. Curigliano
HER2-Low Breast Cancer: a New Subtype?
2023 C. Corti, F. Giugliano, E. Nicolò, P. Tarantino, C. Criscitiello, G. Curigliano
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano
The HER2-low revolution in breast oncology: steps forward and emerging challenges
2023 E. Nicolo, L. Boscolo Bielo, G. Curigliano, P. Tarantino
Biology and Treatment of HER2-Low Breast Cancer
2023 E. Nicolo, P. Tarantino, G. Curigliano
Targeting HER3 for cancer treatment: a new horizon for an old target
2023 J. Uliano, C. Corvaja, G. Curigliano, P. Tarantino
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer
2022 P. Tarantino, Q. Jin, N. Tayob, R.M. Jeselsohn, S.J. Schnitt, J. Vincuilla, T. Parker, S. Tyekucheva, T. Li, N.U. Lin, M.E. Hughes, A.C. Weiss, T.A. King, E.A. Mittendorf, G. Curigliano, S.M. Tolaney
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
2022 E. Nicolò, F. Giugliano, L. Ascione, P. Tarantino, C. Corti, S.M. Tolaney, M. Cristofanilli, G. Curigliano
Bystander effect of antibody-drug conjugates: fact or fiction?
2022 F. Giugliano, C. Corti, P. Tarantino, F. Michelini, G. Curigliano
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents
2022 P. Tarantino, O. D'Ecclesiis, E. Nicolò, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M.A. Locatelli, C. Belli, A. Esposito, I. Minchella, S.M. Tolaney, G. Curigliano
Characterization of low HER2 expressions in de-novo metastatic breast cancer
2021 P. Tarantino, E. Nicolo, P. Zagami, F. Giugliano, P. Aliaga, E. Crimini, C. Corti, J. Uliano, S. Morganti, L. Mazzarella, C. Criscitiello, A. Esposito, G. Curigliano
Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
2021 P. Tarantino, S. Morganti, G. Curigliano